| 来源类型 | Working Paper |
| 规范类型 | 论文 |
| Poor quality drugs and global trade: A pilot study | |
| Roger Bate; Aparna Mathur; Amir Attaran; Ginger Zhe Jin | |
| 发表日期 | 2014-09-08 |
| 出版年 | 2014 |
| 语种 | 英语 |
| 摘要 | Experts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with non-existent, under-developed or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1,470 antibiotic and tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries. We find that 10.9 percent of those products fail a basic assessment of active pharmaceutical ingredients (API), and the majority of the failures are substandard (7 percent) as they contain some correct API but the amount of API is under-dosed. The distribution of these substandard products is not random: they are more likely to be found as unregistered products in Africa than in India or non-African countries. Since this finding is robust for manufacturer-drug fixed effects, one likely explanation is that Indian pharmaceutical firms and/or their export intermediaries do indeed differentiate drug quality according to the destination of consumption. Read the full working paper from the National Bureau of Economic Research. |
| 主题 | Health Care |
| 标签 | Counterfeit pharmaceuticals ; drug industry ; Global health ; International trade ; Pharmaceuticals |
| URL | https://www.aei.org/research-products/working-paper/poor-quality-drugs-and-global-trade-a-pilot-study/ |
| 来源智库 | American Enterprise Institute (United States) |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/207309 |
| 推荐引用方式 GB/T 7714 | Roger Bate,Aparna Mathur,Amir Attaran,et al. Poor quality drugs and global trade: A pilot study. 2014. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
